Scarica l'app Stockscreener
1.005
1.47%
-0.015
Precedente Chiudi:
$1.02
Aprire:
$1.02
Volume 24 ore:
104.02K
Relative Volume:
0.51
Capitalizzazione di mercato:
$59.96M
Reddito:
$8.38M
Utile/perdita netta:
$-27.19M
Rapporto P/E:
-0.922
EPS:
-1.09
Flusso di cassa netto:
$-13.59M
1 W Prestazione:
-1.47%
1M Prestazione:
+16.77%
6M Prestazione:
-4.29%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.9973
$1.03
Intervallo di 1 settimana:
$0.9606
$1.03
Portata 52W:
$0.65
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
Nome
Opus Genetics Inc
Settore
Industria
Telefono
248-681-9815
Indirizzo
8 DAVIS DRIVE, DURHAM
Confronta IRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.005 | 60.85M | 8.38M | -27.19M | -13.59M | -1.09 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-11 | Iniziato | Craig Hallum | Buy |
| 2024-11-13 | Ripresa | H.C. Wainwright | Buy |
Opus Genetics Inc Borsa (IRD) Ultime notizie
Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Opus Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewswire
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data - GuruFocus
Opus Genetics Inc (IRD) Q1 2025 Earnings: EPS of $(0.24) Beats E - GuruFocus
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data | IRD Stock News - GuruFocus
Opus Genetics Q1 2025 Financial Results and Corporate Update - TradingView
Opus Gene Therapy Shows 12-Month Vision Restoration Success, Gains FDA RMAT Status | IRD Stock News - Stock Titan
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Co - GuruFocus
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Conferences | IRD Stock News - GuruFocus
Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025 - Nasdaq
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewswire
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy - Yahoo Finance
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LC - GuruFocus
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LCA5 | IRD Stock News - GuruFocus
FDA grants Opus Genetics RMAT status for eye therapy - Investing.com
Opus Genetics Granted FDA Regenerative Medicine Advanced - GlobeNewswire
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - The Manila Times
FDA grants Opus Genetics RMAT status for eye therapy By Investing.com - Investing.com South Africa
FDA Fast-Tracks Revolutionary Gene Therapy for Ultra-Rare Inherited Blindness Treatment - Stock Titan
Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - The Manila Times
Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire
Gene Therapy Breakthrough: Opus Reports 3.5-Line Vision Improvement After 1 Year in Rare Eye Disease Trial - Stock Titan
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance
Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria
Opus Genetics shareholders approve key proposals - Investing.com
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com
Opus Genetics (NASDAQ:IRD) Research Coverage Started at Craig Hallum - Defense World
Opus Genetics (IRD) Receives Buy Rating with Promising Gene Ther - GuruFocus
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - The Manila Times
Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit Business
Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Mina Sooch Issues Open Letter To Opus Genetics' Stockholders - marketscreener.com
Night Vision Disturbances Market to Reach New Heights in Growth - openPR.com
Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board - MarketScreener
Opus Genetics Inc Azioni (IRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
8.70%
1.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):